期刊
CLINICAL RHEUMATOLOGY
卷 37, 期 6, 页码 1715-1720出版社
SPRINGER LONDON LTD
DOI: 10.1007/s10067-018-4092-4
关键词
Behcet's disease; Disease activity; Long-termefficacy; Treatment; Uveitis
类别
To identify clinical variables capable of predicting long-term treatment duration of TNF-alpha inhibition in patients with Behcet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-alpha blockers infliximab and adalimumab. Patients still continuing TNF-alpha inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit. Forty-five patients (75 eyes) were enrolled. Thirty-two patients continued anti-TNF-alpha treatment for more than 48 months; 13 patients discontinued the treatment after a mean time of 12.3 +/- 10.44 months due to lack (61.5%) or loss (38.5%) of efficacy. Baseline value of BD current activity form was the only variable discriminating long- and short-term responsive patients (p = 0.048, OR = 0.656, C.I. 95% 0.433-0.996). Disease activity levels at the start of treatment predict duration of response to monoclonal TNF antagonists in ocular BD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据